SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-17-008297
Filing Date
2017-05-08
Accepted
2017-05-08 16:35:50
Documents
50
Period of Report
2017-05-02

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q avir20170502_10q.htm 10-Q 684012
2 EXHIBIT 10.1 ex10-1.htm EX-10.1 61857
3 EXHIBIT 31.1 ex31-1.htm EX-31.1 17791
4 EXHIBIT 31.2 ex31-2.htm EX-31.2 17820
5 EXHIBIT 32.1 ex32-1.htm EX-32.1 12270
  Complete submission text file 0001437749-17-008297.txt   3476351

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT avir-20170331.xml EX-101.INS 737253
7 XBRL TAXONOMY EXTENSION SCHEMA avir-20170331.xsd EX-101.SCH 35052
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE avir-20170331_cal.xml EX-101.CAL 28127
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE avir-20170331_def.xml EX-101.DEF 214615
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20170331_lab.xml EX-101.LAB 192136
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20170331_pre.xml EX-101.PRE 233748
Mailing Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009
Business Address 2500 NORTHWINDS PARKWAY, SUITE 100 ALPHARETTA 2Q 30009 301-770-3099
Aviragen Therapeutics, Inc. (Filer) CIK: 0000072444 (see all company filings)

IRS No.: 591212264 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-35285 | Film No.: 17822953
SIC: 2836 Biological Products, (No Diagnostic Substances)